Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search
2015 Press Releases

XORTX Pharma Corp. Announces Grant of US Patent for the Treatment of Diabetic Nephropathy

  • October 15, 2015December 22, 2020
  • by aaronbb

XORTX Pharma Corp. – a company focused on the development of drugs to treat orphan and non-orphan kidney diseases – is pleased to announce the Issuance of a U.S. Patent No. 9,155,740, entitled “COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES”.
› Read more

Press Releases

  • XORTX Provides Corporate Update January 19, 2021
  • XORTX Grants Options January 12, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Grant of European Patent December 29, 2020
  • XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study November 16, 2020

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress